Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma - PubMed
14 hours ago
- #Melanoma
- #T-cell response
- #Immunotherapy
- Prednisolone affects CD8+ and regulatory T-cell activity, reducing the effectiveness of immune checkpoint inhibitor (ICI) therapy in melanoma.
- Systemic prednisolone, when used after anti-CTLA4 and anti-PD1 therapy, compromises tumor control and delays progression in some cases.
- Prednisolone suppresses CD8+ effector T-cell activation while expanding regulatory T-cells, altering the Treg:CD8+ effector ratio.
- The treatment reduces cytotoxic T-cell function and blocks early ICI-mediated cytokine induction.
- Long-term tumor-specific memory responses remain intact despite early immunosuppressive effects.
- The study highlights the importance of timing and context when introducing corticosteroids during ICI therapy.